Chlorambucil
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
Chlorambucil: ALK-positive large B-cell lymphoma
One-Sentence Summary
Chlorambucil is an oral alkylating agent that is marketed in Australia as a 2 mg tablet. There are no registered clinical trials and 1 publication (a 2003 review) for this exact subtype, so support is indirect only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | ALK-positive large B-cell lymphoma |
| TxGNN Prediction Score | 0.9961 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available in the data compiled for this report. Chlorambucil is a nitrogen mustard-type alkylating agent, a class that damages DNA in dividing cells, and this class has long been used in B-cell lymphoproliferative disorders.
The predicted disease is a molecular subtype (unmutated immunoglobulin gene, pre-germinal centre type) of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Mechanistically, a drug active in CLL/SLL would be expected to act on this subtype too. The very high score probably reflects closeness to the parent disease rather than subtype-specific evidence. The prediction is therefore better viewed as a subtype of an established disease family than as a true repurposing candidate.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 12577769 | 2003 | Review | Nederlands tijdschrift voor geneeskunde | Describes two CLL subtypes (pre-germinal centre type with unmutated immunoglobulin genes) and argues for a risk-adapted approach. It does not test chlorambucil in this subtype. |
Australia Market Information
| ARTG Number | Product Name | Dosage Form |
|---|---|---|
| ARTG 1163F | Leukeran | Tablet 2 mg |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (alkylating agent, nitrogen mustard class) |
| Myelosuppression Risk | High (bone marrow suppression is a recognised dose-related effect) |
| Emetogenicity Classification | Low |
| Monitoring Items | Full blood count with differential, liver and renal function |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Please also refer to the Product Information (PI) warnings and precautions.
Safety Considerations
- Drug Interactions (100 interactions were recorded; selected examples by severity):
- Major: deferiprone, samarium (153Sm) lexidronam
- Moderate: amphotericin B (including lipid complex, cholesteryl sulfate and liposomal forms), palifermin, strontium chloride Sr-89, mercaptopurine, roflumilast, chloramphenicol
- Minor: levofloxacin
- Conditions flagged for caution in the data compiled for this report (not taken from label text): epilepsy, cytopenias (thrombocytopenia, neutropenia, leukopenia, lymphopenia, anaemia, agranulocytosis), nephrotic syndrome, interstitial lung disease and pulmonary fibrosis, drug-induced liver injury, and acute leukaemia.
Please refer to the TGA-approved Product Information (PI) for the authoritative warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: No cited study directly tests chlorambucil in this subtype, so the evidence level is L5 (model prediction only). The single publication is a general review. The subtype sits inside a disease family where chlorambucil is already used, so the question is more one of clinical positioning than of new repurposing.
To proceed, the following is needed:
- Subtype-specific clinical data (for example, outcomes by immunoglobulin gene mutation status in patients treated with chlorambucil)
- Comparison with current standard CLL/SLL therapies, since newer targeted agents have largely replaced chlorambucil in many settings
- Mechanism of action data
- Warnings and contraindications from the TGA Product Information, followed by a safety review
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.